Expand CATX Menu
CATX MENU

CATX Latest Press Releases

-- January 13, 2025 --

Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference Globe Newswire 8:00 AM

-- January 10, 2025 --

Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference Globe Newswire 7:00 AM

-- January 6, 2025 --

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer Globe Newswire 8:00 AM

-- November 27, 2024 --

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December Globe Newswire 7:00 AM

-- November 21, 2024 --

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium Globe Newswire 7:15 AM

-- November 15, 2024 --

Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 Globe Newswire 4:08 PM

-- November 12, 2024 --

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results Globe Newswire 4:05 PM

-- October 31, 2024 --

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results Globe Newswire 7:00 AM

-- October 29, 2024 --

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November Globe Newswire 7:00 AM

-- October 23, 2024 --

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine Globe Newswire 7:00 AM

-- October 16, 2024 --

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey Globe Newswire 7:00 AM

-- October 11, 2024 --

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research Globe Newswire 8:30 AM

-- October 10, 2024 --

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research Globe Newswire 5:14 PM

-- October 7, 2024 --

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day Globe Newswire 7:00 AM

-- September 30, 2024 --

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine Globe Newswire 7:00 AM

-- September 10, 2024 --

Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024 Globe Newswire 7:00 AM

-- September 5, 2024 --

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma Globe Newswire 7:00 AM

-- August 28, 2024 --

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September Globe Newswire 7:00 AM